Septic Candida krusei thrombophlebitis of inferior vena cava with persistent fungemia successfully treated by new antifungal agents.
暂无分享,去创建一个
[1] T. Peláez,et al. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. , 2005, The Journal of antimicrobial chemotherapy.
[2] B. Barlogie,et al. Deep septic thrombophlebitis: an unrecognized cause of relapsing bacteremia in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Sobel,et al. Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[5] J. Graybill,et al. In Vitro Activity of Caspofungin against Candida albicans Biofilms , 2002, Antimicrobial Agents and Chemotherapy.
[6] B. Wickes,et al. In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies , 2002, Antimicrobial Agents and Chemotherapy.
[7] J. Reekers,et al. Prospective Study of Color Duplex Ultrasonography Compared with Contrast Venography in Patients Suspected of Having Deep Venous Thrombosis of the Upper Extremities , 2002, Annals of Internal Medicine.
[8] M. Ghannoum,et al. Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.
[9] M. Pfaller,et al. Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000 , 2002, Journal of Clinical Microbiology.
[10] J. Rex,et al. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] B. Wickes,et al. Biofilms of Candida albicans and their associated resistance to antifungal agents. , 2001, American clinical laboratory.
[12] G. Bodey,et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. , 2000, Archives of internal medicine.
[13] D. Sheehan,et al. Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.
[14] F. Vermassen,et al. Management of candidal thrombophlebitis of the central veins: case report and review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] R. Delcore,et al. Thrombolytic therapy for catheter-related thrombosis. , 1993, American journal of surgery.
[16] G. Bodey,et al. Azole antifungal agents. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] Anand Vk,et al. Thrombophlebitis of the jugular vein. , 1987 .
[18] M. Topiel,et al. Treatment of silastic catheter-induced central vein septic thrombophlebitis. , 1986, The American journal of the medical sciences.
[19] R. Arbeit,et al. Central Venous Septic Thrombophlebitis—The Role of Medical Therapy , 1985, Medicine.
[20] E. Pollak,et al. Subclavian‐Axillary Venous Thrombosis: Role of Noninvasive Diagnostic Methods , 1980, Southern medical journal.
[21] J. Norante,et al. Thrombophlebitis of the internal jugular vein secondary to pharyngitis. , 1980, Archives of otolaryngology.
[22] D. Maki,et al. Management of septic thrombosis of the inferior vena cava caused by Candida. , 1978, Archives of surgery.
[23] A. Munster. Septic thrombophlebitis. A surgical disorder. , 1974, JAMA.
[24] J. Wingard,et al. Importance of Candida species other than C. albicans as pathogens in oncology patients. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.